Interleukin-6 is considered a potential biomarker linking rheumatoid arthritis and malignant tumors, with the potential to monitor RA associated malignant tumors, but further experimental evidence is needed (96).Time has been considered by some studies as the method to determine the complications (89), but there are inevitably many interfering factors, making time not the best diagnostic method. The gene discussed is IL6; the disease is cancer.